🇪🇺 EXPAREL Infiltration in European Union

EMA authorised EXPAREL Infiltration on 16 November 2020

Marketing authorisation

EMA — authorised 16 November 2020

  • Application: EMEA/H/C/004586
  • Marketing authorisation holder: Pacira Ireland Limited
  • Local brand name: Exparel liposomal
  • Indication: Exparel liposomal is indicated: in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.
  • Status: approved

Read official source →

EXPAREL Infiltration in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is EXPAREL Infiltration approved in European Union?

Yes. EMA authorised it on 16 November 2020.

Who is the marketing authorisation holder for EXPAREL Infiltration in European Union?

Pacira Ireland Limited holds the EU marketing authorisation.